Single, very low rituximab doses in healthy volunteers - a pilot and a randomized trial: implications for dosing and biosimilarity testing-Reference-Cited by-同舟云学术

Single, very low rituximab doses in healthy volunteers - a pilot and a randomized trial: implications for dosing and biosimilarity testing

Published:2018-01-09 Issue:1 Volume:8 Page:
ISSN:2045-2322
Container-title:Scientific Reports
language:en
Short-container-title:Sci Rep

Author:

Schoergenhofer Christian,Schwameis Michael,Firbas Christa,Bartko Johann,Derhaschnig Ulla,Mader Robert M^ORCID,Plaßmann Raute Sunder,Jilma-Stohlawetz Petra,Desai Kalpna,Misra Priya,Jäger Ulrich,Jilma Bernd

Publisher

Springer Science and Business Media LLC

Subject

Multidisciplinary

Link

http://www.nature.com/articles/s41598-017-17934-6.pdf

Reference30 articles.

1. Maloney, D. G. et al. Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma. Blood 84, 2457–2466 (1994).

2. McLaughlin, P. Rituximab: perspective on single agent experience, and future directions in combination trials. Crit Rev Oncol Hematol 40, 3–16 (2001).

3. Iacona, I. et al. Rituximab (IDEC-C2B8): validation of a sensitive enzyme-linked immunoassay applied to a clinical pharmacokinetic study. Ther Drug Monit 22, 295–301 (2000).

4. Smolen, J. S., Aletaha, D. & McInnes, I. B. Rheumatoid arthritis. Lancet. https://doi.org/10.1016/S0140-6736(16)30173-8 (2016).

5. Scott, D. L. Biologics-based therapy for the treatment of rheumatoid arthritis. Clin Pharmacol Ther 91, 30–43, https://doi.org/10.1038/clpt.2011.278 (2012).

Cited by 33 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A study of ultralow dose rituximab as adjuvant to standard of care in treatment of significant and extensive pemphigus vulgaris: A case series;Journal of the American Academy of Dermatology;2024-09

2. Updates on the Management of Autoimmune Bullous Diseases;Indian Dermatology Online Journal;2024-08-30

3. Ultra-low-dose rituximab is effective for the treatment of patients with minimal change disease - A retrospective study;Journal of the Formosan Medical Association;2024-06

4. Unexpected B lymphocytes depletion in a patient with pemphigus vulgaris after a single dose of 50 mg rituximab;The Journal of Dermatology;2024-05-22

5. Comparison of the efficacy of steroid-free versus classic steroid-containing regimens in primary membranous nephropathy;Frontiers in Pharmacology;2024-02-14